Published in Biotech Business Week, July 25th, 2005
The dose-range study assessed efficacy, safety and tolerability of inhaled LAS34273 administered once-daily in patients with moderate to severe stable chronic obstructive pulmonary disease compared with placebo. This large study was composed of a total of 48 centers across seven European countries and it included 464 randomized patients in the trial.
Results demonstrate that LAS34273 has a sustained 24-h bronchodilator effect; an effect that was rapidly observed and was maintained...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.